137 related articles for article (PubMed ID: 26982394)
1. Menstrual cyclicity post OC withdrawal in PCOS: Use of non-hormonal options.
Kulshreshtha B; Arora A; Pahuja I; Sharma N; Pant S
J Obstet Gynaecol; 2016 Aug; 36(6):833-838. PubMed ID: 26982394
[TBL] [Abstract][Full Text] [Related]
2. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
3. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
Burchall GF; Piva TJ; Ranasinha S; Teede HJ
Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
[No Abstract] [Full Text] [Related]
4. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
5. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
de Zegher F; Díaz M; Villarroya J; Cairó M; López-Bermejo A; Villarroya F; Ibáñez L
Sci Rep; 2021 Mar; 11(1):7018. PubMed ID: 33782413
[TBL] [Abstract][Full Text] [Related]
6. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
[TBL] [Abstract][Full Text] [Related]
7. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
9. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
La Marca A; Grisendi V; Dondi G; Sighinolfi G; Cianci A
Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
[TBL] [Abstract][Full Text] [Related]
10. Best methods for identification and treatment of PCOS.
Artini PG; Di Berardino OM; Simi G; Papini F; Ruggiero M; Monteleone P; Cela V
Minerva Ginecol; 2010 Feb; 62(1):33-48. PubMed ID: 20186113
[TBL] [Abstract][Full Text] [Related]
11. Metformin treatment is effective in obese teenage girls with PCOS.
De Leo V; Musacchio MC; Morgante G; Piomboni P; Petraglia F
Hum Reprod; 2006 Sep; 21(9):2252-6. PubMed ID: 16785260
[TBL] [Abstract][Full Text] [Related]
12. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
Ganie MA; Khurana ML; Eunice M; Gupta N; Gulati M; Dwivedi SN; Ammini AC
J Clin Endocrinol Metab; 2004 Jun; 89(6):2756-62. PubMed ID: 15181054
[TBL] [Abstract][Full Text] [Related]
14. The treatment of polycystic ovary syndrome.
Ajossa S; Guerriero S; Paoletti AM; Orrù M; Melis GB
Minerva Ginecol; 2004 Feb; 56(1):15-26. PubMed ID: 14973407
[TBL] [Abstract][Full Text] [Related]
15. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study.
Cinar N; Harmanci A; Demir B; Yildiz BO
Hum Reprod; 2012 Jun; 27(6):1840-5. PubMed ID: 22473394
[TBL] [Abstract][Full Text] [Related]
16. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.
Fulghesu AM; Romualdi D; Di Florio C; Sanna S; Tagliaferri V; Gambineri A; Tomassoni F; Minerba L; Pasquali R; Lanzone A
Hum Reprod; 2012 Oct; 27(10):3057-66. PubMed ID: 22786777
[TBL] [Abstract][Full Text] [Related]
17. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
[TBL] [Abstract][Full Text] [Related]
18. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Al Khalifah RA; Flórez ID; Dennis B; Neupane B; Thabane L; Bassilious E
Syst Rev; 2015 Sep; 4():125. PubMed ID: 26420636
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
Ezeh U; Huang A; Landay M; Azziz R
J Womens Health (Larchmt); 2018 Jul; 27(7):892-902. PubMed ID: 29878857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
